Blog
RSS FeedPosted by Michael Wonder on 02 Aug 2023
Ganaxolone for the treatment of patients with seizures caused by CDKL5 deficiency disorder
2 August 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 01 Aug 2023
Zanubrutinib for the treatment of patients with chronic lymphocytic leukaemia
1 August 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 28 Jul 2023
Talazoparib tosylate for the treatment of patients with advanced, germline BRCA mutation positive, HER2 negative breast cancer
28 July 2023 - NICE has published preliminary evidence-based recommendations on the use of talazoparib tosylate (Talzenna) for the treatment of ...
Posted by Michael Wonder on 26 Jul 2023
Afamelanotide acetate for the treatment of patients with erythropoietic protoporphyria
27 July 2023 - NICE has published final evidence-based recommendations on the use of afamelanotide acetate (Scenesse) for the treatment ...
Posted by Michael Wonder on 26 Jul 2023
Selpercatinib for untreated RET fusion positive advanced non-small-cell lung cancer
26 July 2023 - NICE has published final evidence-based recommendations on the use of selpercatinib (Retsevmo) for adults with advanced, ...
Posted by Michael Wonder on 24 Jul 2023
Ethics information retrieval in HTA: state of current practice
19 July 2023 - This study aimed to scope available evidence and determine current practices for ethics information retrieval in HTA. ...
Posted by Michael Wonder on 20 Jul 2023
New Government consultation on medicine clawbacks will harm investment, says ABPI
19 July 2023 - In a move that will further damage UK life sciences investment, the Government has launched a ...
Posted by Michael Wonder on 13 Jul 2023
Semaglutide for the treatment of overweight and obese adolescents
13 July 2023 - NICE is unable to make a recommendation on the use of semaglutide (Wegovy) on the NHS for ...
Posted by Michael Wonder on 12 Jul 2023
Lorlatinib for the treatment of adults with advanced ALK positive non-small-cell lung cancer
12 July 2023 - NICE has published final evidence-based recommendations on the use of lorlatinib (Lorviqua) for the treatment of ...
Posted by Michael Wonder on 05 Jul 2023
Rimegepant sulphate for the prevention of migraine
5 July 2023 - NICE has published final evidence-based recommendations on the use of rimegepant sulphate (Vydura) for the prevention ...
Posted by Michael Wonder on 05 Jul 2023
Olaparib for the maintenance treatment of adults with relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after two or more courses of platinum-based chemotherapy
5 July 2023 - NICE has published final evidence-based recommendations on the use of olaparib (Lynparza) for the maintenance treatment ...
Posted by Michael Wonder on 29 Jun 2023
Secukinumab for the treatment of patients with moderate to severe hidradenitis suppurativa
29 June 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 28 Jun 2023
Deucravacitinib for the treatment of patients with moderate to severe plaque psoriasis
28 June 2023 - NICE has published final evidence-based recommendations on the use of deucravacitinib for the treatment of adults ...
Posted by Michael Wonder on 27 Jun 2023
NICE launches public consultation on updates to health technology evaluations manual
27 June 2023 - A public consultation on updates to NICE’s health technology evaluations manual is now open. ...
Posted by Michael Wonder on 27 Jun 2023
More evidence needed to recommend type 2 diabetes treatment tirzepatide
27 June 2023 - More evidence is needed on the clinical and cost effectiveness of a new treatment option for patients ...